NFKB1 and breast cancer: Among the developed sialyltransferase inhibitors, compounds such as FCW34 and FCW66 have demonstrated efficacy in reducing BC cell migration, metastasis, and tumor growth by altering N-glycan sialylation and affecting key signaling pathways such as talin/integrin/FAK/paxillin and integrin/NFκB [134].